RUNX1 and myelodysplastic syndrome: In addition, in a recently report [53] on 79 MDS patients showing +8 isolated cytogenetic alterations, the mutational profile identified an HR subgroup with mutations in STAG2, SRSF2, and/or RUNX1, resulting in independent prognostic factors of a shorter time to AML evolution and overall survival (OS).